European Players Wake Up to Japanese Opportunities

European biotech companies have historically shied away from regional transactions in Japan, instead lumping Japanese rights into global deals with more familiar Western counterparts. But some recent deals indicate that they're beginning to recognize the significant value in separating out Japanese rights. Particularly since nowadays, licensing in Japan needn't be any more challenging than it is anywhere else.

Historically, European biotechs have concluded few regional licensing deals for Japan. Despite being the second largest pharmaceutical market in the world with sales in excess of $50 billion, the time, distance, language and cultural barriers were considered too challenging. Moreover, companies perceived it was only possible to get decent value if they were licensing potential blockbusters. And they also feared that signing away Japanese rights might jeopardize their chances of attracting Big Pharma, who would want global rights.

But things appear to be changing. While the number of deals is still small—Windhover's Strategic Intelligence Systems Database has tracked...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo